Back

Cost analysis of a nationwide typhoid conjugate vaccine campaign in Burkina Faso

Koulidiati, J.-L.; Zoma, R. L.; Nebie, E. I.; Soumaila, Y.; Neya, C. O.; Kiendrebeogo, J. A.; Debellut, F.

2026-04-25 health economics
10.64898/2026.04.17.26350856 medRxiv
Show abstract

BackgroundIn Burkina Faso, typhoid fever remains a major public health concern, with a high incidence among children younger than 15 years of age. To address this burden, the country introduced typhoid conjugate vaccine in January 2025 through a national vaccination campaign reaching children aged 9 months to 14 years. This study aimed to estimate the cost of typhoid conjugate vaccine delivery during the national campaign and to identify the main cost drivers across different administrative levels. MethodsWe conducted a cross-sectional, retrospective costing study using a microcosting approach from the government perspective. We collected data from fifty health facilities, eight health districts, five health regions, and the national level. Financial and economic costs were estimated for each level, excluding vaccine and syringe costs. All costs were converted to 2024 USD using the official exchange rate. FindingsVaccinators administered a total of 10.5 million typhoid conjugate vaccine doses. The average financial cost per dose was $0.47 (95% CI: $0.39-$0.51), and the economic cost was $2.16 (95% CI: $1.71-$2.56). Human resources and per diem payments were the main contributors to costs. Costs varied by geography, delivery strategy, and security context, with higher costs observed in rural and conflict-affected areas. The mobile-temporary posts strategy had the highest economic cost per dose ($2.02; 95% CI: $1.64-$2.40), while the fixed strategy had the highest financial cost per dose ($0.41; 95% CI: ($0.32-$0.49). ConclusionThe financial cost per dose remained within Gavi, the Vaccine Alliances operational support range. The observed cost variations highlight the need for targeted funding and enhanced logistical support to ensure equitable access, particularly in rural and insecure areas. This study provides evidence to inform future vaccination campaigns and supports decision-making for typhoid conjugate vaccine introduction in other countries in the region.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Vaccine
189 papers in training set
Top 0.1%
21.7%
2
PLOS Neglected Tropical Diseases
378 papers in training set
Top 0.6%
16.9%
3
BMJ Global Health
98 papers in training set
Top 0.3%
8.8%
4
PLOS Global Public Health
293 papers in training set
Top 1%
8.1%
50% of probability mass above
5
BMC Public Health
147 papers in training set
Top 1%
4.1%
6
Travel Medicine and Infectious Disease
15 papers in training set
Top 0.1%
3.8%
7
The American Journal of Tropical Medicine and Hygiene
60 papers in training set
Top 1%
3.5%
8
Vaccine: X
19 papers in training set
Top 0.1%
3.5%
9
BMJ Open
554 papers in training set
Top 6%
3.5%
10
BMC Health Services Research
42 papers in training set
Top 0.7%
3.1%
11
Public Health Nutrition
14 papers in training set
Top 0.2%
3.0%
12
Vaccines
196 papers in training set
Top 0.8%
2.5%
13
PLOS ONE
4510 papers in training set
Top 46%
2.3%
14
The Lancet Infectious Diseases
71 papers in training set
Top 2%
1.6%
15
Frontiers in Public Health
140 papers in training set
Top 6%
1.3%
16
eClinicalMedicine
55 papers in training set
Top 1%
0.9%
17
Journal of Medical Economics
10 papers in training set
Top 0.1%
0.9%
18
BMC Medicine
163 papers in training set
Top 6%
0.9%
19
Environmental Research Letters
15 papers in training set
Top 0.6%
0.7%
20
Scientific Reports
3102 papers in training set
Top 77%
0.7%
21
npj Vaccines
62 papers in training set
Top 0.5%
0.7%
22
PLOS Medicine
98 papers in training set
Top 5%
0.6%
23
Eurosurveillance
80 papers in training set
Top 2%
0.6%